A Randomized Trial of Zoledronic Acid to Prevent Bone Loss in the First Year after Kidney Transplantation.

Affiliation

Urology Division, Renal Transplant Service and [Email]

Abstract

Bone and mineral disorders commonly affect kidney transplant (KTx) recipients and have been associated with a high risk of fracture. Bisphosphonates may prevent or treat bone loss in such patients, but there is concern that these drugs might induce adynamic bone disease (ABD).

Keywords

bone biopsy,kidney disease,kidney transplantation,mineral metabolism,renal osteodystrophy,zoledronic acid,

OUR Recent Articles